491 related articles for article (PubMed ID: 18294387)
1. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
[TBL] [Abstract][Full Text] [Related]
2. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
Ghebeh H; Mohammed S; Al-Omair A; Qattan A; Lehe C; Al-Qudaihi G; Elkum N; Alshabanah M; Bin Amer S; Tulbah A; Ajarim D; Al-Tweigeri T; Dermime S
Neoplasia; 2006 Mar; 8(3):190-8. PubMed ID: 16611412
[TBL] [Abstract][Full Text] [Related]
3. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.
Hou J; Yu Z; Xiang R; Li C; Wang L; Chen S; Li Q; Chen M; Wang L
Exp Mol Pathol; 2014 Jun; 96(3):284-91. PubMed ID: 24657498
[TBL] [Abstract][Full Text] [Related]
4. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration.
Zhao LW; Li C; Zhang RL; Xue HG; Zhang FX; Zhang F; Gai XD
Acta Histochem; 2014 Sep; 116(7):1163-8. PubMed ID: 25053455
[TBL] [Abstract][Full Text] [Related]
5. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
6. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Karim R; Jordanova ES; Piersma SJ; Kenter GG; Chen L; Boer JM; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Oct; 15(20):6341-7. PubMed ID: 19825956
[TBL] [Abstract][Full Text] [Related]
7. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance.
Geng Y; Wang H; Lu C; Li Q; Xu B; Jiang J; Wu C
Int J Clin Oncol; 2015 Apr; 20(2):273-81. PubMed ID: 24804867
[TBL] [Abstract][Full Text] [Related]
8. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.
Boorjian SA; Sheinin Y; Crispen PL; Farmer SA; Lohse CM; Kuntz SM; Leibovich BC; Kwon ED; Frank I
Clin Cancer Res; 2008 Aug; 14(15):4800-8. PubMed ID: 18676751
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.
Jacobs JF; Idema AJ; Bol KF; Nierkens S; Grauer OM; Wesseling P; Grotenhuis JA; Hoogerbrugge PM; de Vries IJ; Adema GJ
Neuro Oncol; 2009 Aug; 11(4):394-402. PubMed ID: 19028999
[TBL] [Abstract][Full Text] [Related]
12. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
[TBL] [Abstract][Full Text] [Related]
13. FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
Giatromanolaki A; Banham AH; Harris AL; Koukourakis MI
Exp Lung Res; 2019; 45(3-4):76-83. PubMed ID: 31134811
[No Abstract] [Full Text] [Related]
14. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
15. Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy.
Alderson KL; Zhou Q; Berner V; Wilkins DE; Weiss JM; Blazar BR; Welniak LA; Wiltrout RH; Redelman D; Murphy WJ
J Immunol; 2008 Mar; 180(5):2981-8. PubMed ID: 18292520
[TBL] [Abstract][Full Text] [Related]
16. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.
Hua D; Sun J; Mao Y; Chen LJ; Wu YY; Zhang XG
World J Gastroenterol; 2012 Mar; 18(9):971-8. PubMed ID: 22408358
[TBL] [Abstract][Full Text] [Related]
17. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
[TBL] [Abstract][Full Text] [Related]
18. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
19. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
20. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Syed Khaja AS; Toor SM; El Salhat H; Faour I; Ul Haq N; Ali BR; Elkord E
Oncotarget; 2017 May; 8(20):33159-33171. PubMed ID: 28388539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
